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Abstract
Background: Occupational sharps injuries are associated with transmission of bloodborne viruses to healthcare
workers, including hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Similarly
reuse of syringes in healthcare settings might transmit these infections between patients. The objective of this
study was to systematically review the evidence about the effects of the use by health care workers of two types of
safety engineered injection devices, when delivering intramuscular, subcutaneous, or intradermal injectable medications:
sharps injury protection syringes and reuse prevention syringes.
Methods: We included both randomized and non-randomized studies comparing safety syringes to syringes without
safety features. Outcomes of interest included needlestick injuries, and HIV, HBV and HCV infections amongst HCWs (for
sharps injury prevention syringes) and patients (for reuse prevention syringes). When possible, we conducted meta-
analyses using a random-effects model. We tested results for heterogeneity across studies using the I statistic. We
assessed the quality of evidence by outcome using the GRADE methodology.
Results: We included nine eligible studies: six assessed devices that qualify as sharps injury prevention devices, and three
assessed devices that qualify as both injury prevention devices and reuse prevention devices. Eight studies were
observational while one was randomized. All studies assessed a single outcome: needle stick injuries among healthcare
workers. For sharp injury prevention syringes, the meta-analysis of five studies resulted in a pooled relative risk of 0.54
[0.41, 0.71] for the effect on needlestick injuries per healthcare worker. The associated quality of evidence was rated as
moderate. For reuse prevention syringes, data from one study provided a relative risk of 0.40 [0.27, 0.59] for the effect on
needlestick injuries per healthcare worker. The associated quality of evidence was rated as moderate. We identified no
studies reporting on the effect on the reuse of syringes.
Conclusions: We identified moderate quality evidence that syringes with sharps injury prevention feature reduce the
incidence of needlestick injuries per healthcare worker. We identified no studies reporting data for the remaining
outcomes of interest for HCWs. Similarly we identified no studies reporting on the effect of syringes with a reuse
prevention feature on the reuse of syringes or on the other outcomes of interest for patients.
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Background
Healthcare workers (HCWs) exposure to bloodborne
pathogens from sharps injuries, primarily needlesticks, is a
serious occupational problem. The World Health
Organization (WHO) reported that more than three
million HCWs were exposed to bloodborne pathogens
from percutaneous exposure in the year 2000 across the
world [1]. In the United States alone, and according to the
Centers for Disease Control and Prevention (CDC),
hospital-based HCWs suffer about 385,000 such injuries
annually. This amounts to an average of 1000 injuries per
day [2]. In the United Kingdom, sharps injuries account for
17 % of accidents to the National Health Services staff [3].
Occupational sharps injuries are associated with trans-
mission of bloodborne viruses, the most serious and poten-
tially fatal of which are hepatitis B virus (HBV), hepatitis C
virus (HCV), and human immunodeficiency virus (HIV)
[4, 5]. They are also associated in the transmission of more
than 20 other pathogens [4, 5]. It has been estimated that
occupational sharps injuries are responsible for 32 % of
HBV infections, 40 % of HCV infections, and 5 % of HIV
infections [6]. The HCWs risk of sharp injury related infec-
tion is relatively high in Africa, where HIV is prevalent and
HBV is endemic amongst the patient population [7].
The burden of sharp injuries affects both HCWs and
healthcare institutions. Sharp injury related blood-borne
infections lead to absenteeism, morbidity and, mortality
among HCWs [8]. They may also induce psychological
stress, and negatively affect the personal and work life of
HCWs [9, 10]. Hospitals also suffer from costs related to
testing, treatment, and lost working time [11].
Reuse of syringes in healthcare settings can transmit
these infections between patients. In the year 2000, the
reuse of injection equipment accounted for 32, 40 and
5 % of new HBV, HCV, and HIV infections worldwide
[12]. The estimated burden related to this practice is
around 9.18 million disability-adjusted life years (DALYs)
between the years 2000 and 2030 [13].
One of the suggested interventions to reduce sharps
related injuries is the use of safety-engineered devices,
which have mechanisms to prevent percutaneous injuries
[14]. Indeed, introducing the use of these devices may pre-
vent sharp injuries and the associated bloodborne infec-
tions [15]. Safety features of safety-engineered devices are
designed to shield the needle or non-needle sharp object
after use. There are also two main types of safety syringes:
(1) Sharps injury prevention syringes: these use
different mechanisms e.g. self-retractable needles,
internal blunt needles, or external shielding
(2) Reuse prevention– syringes: these include a reuse
prevention feature e.g. metal clip to block the
plunger once the injection is given, the plunger
breaks etc. (making them unusable after initial use).
We conducted this study in preparation for the devel-
opment of WHO policy guidance on use of safety-
engineered devices by healthcare workers to deliver IM,
SC and ID injections. The objective was to systematically
review the evidence about the effects of the use by
health care workers of two types of safety devices: sharps
injury prevention syringes and reuse prevention syringes.
The specific review questions were:
1. What are the benefits and harms of sharps injury
prevention syringes versus single use disposable
syringes when used by healthcare workers to deliver
intramuscular, subcutaneous or intradermal
injections to patients?
2. What are the benefits and harms of reuse prevention
syringes versus single use disposable syringes when
used by healthcare workers to deliver intramuscular,
subcutaneous or intradermal injections to patients?
Methods
The study consisted of a review of the literature and did
not involve any ‘human subjects’.
Protocol and registration
We developed two separate protocols for sharp injury
prevention syringes and reuse prevention syringes. We
registered the protocols with the International database
of prospectively registered systematic reviews in health
and social care (PROSPERO) [10, 11].
Eligibility criteria
Types of studies included
We included both randomized trials and non-randomized
studies including:
 Cohort studies
 Case control studies
 Before and after studies
 Time-series analysis
We excluded scientific meeting abstracts, research let-
ters, qualitative studies, letters to the editor, reviews, case
reports, and case series.
Types of participants and settings
We included studies of healthcare workers delivering
intramuscular, subcutaneous, or intradermal injectable
medications. We were not interested in non-healthcare
settings (e.g., illicit drug use, patients using insulin pen
needles). We were not interested in other types of injec-
tions (e.g., phlebotomy or intravenous, articular, intra
cardiac, and intra peritoneal injections).
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Types of interventions
We included studies assessing the introduction of a
safety device (sharp injury prevention syringes or reuse
prevention syringes) into a healthcare setting. This intro-
duction could have been accompanied by training of
HCWs. Eligible sharp injury prevention syringes included:
retractable syringes; needle shields, and recapping devices;
needleless injectors; needle-safety devices; Eligible reuse
prevention syringes included: auto-disable syringes (earlier
called “auto-destruct syringes”) (ISO 7886–3), typically
meant for vaccination; reuse prevention devices for thera-
peutic injections (ISO 7886–4); and pre-filled syringe with
reuse prevention feature.
Ineligible devices included: intravenous devices; need-
less adaptors; fistula needle; IV catheters; winged steel
needle; implantable port needles; suture needles; all
blood collection devices (lancet devices, vacuum tubes
for blood collection devices, an arterial blood syringes).
We included studies assessing the introduction of both
eligible and ineligible devices as long as they reported
data for eligible devices separately. We included the
studies not reporting data for eligible devices separately
in a sensitivity analysis.
Types of comparison(s)
We included studies comparing one of the interven-
tions of interest to using a device without a safety fea-
ture, such as the ‘single use disposable syringes’ (ISO
7886–1).
Outcomes
We included studies assessing at least one of the follow-
ing outcomes for sharps injury prevention syringes:
 HIV, HBV, and HCV infections amongst HCWs
 Other blood-borne infections (e.g. viral hemorrhagic
fevers) amongst HCWs
 Abscesses (septic, aseptic) amongst HCWs
 Needlestick injuries amongst HCWs
 Quality of life amongst HCWs
 Social impact (e.g., stigma, job loss) amongst HCWs
We included studies assessing at least one of the fol-
lowing outcomes for reuse prevention syringes:
 Reuse of syringes
 HIV, HBV, and HCV infections amongst patients.
 Other blood-borne infections (e.g. viral hemorrhagic
fevers) amongst patients
 Quality of life amongst patients
 Social impact (e.g., stigma, loss of job) amongst
patients
 Needlestick injuries, HIV, HBV, and HCV infections
amongst HCWs
Any positive impact on those outcomes would be con-
sidered as a benefit, while any negative impact on these
same outcomes would be considered as harm.
Literature search
We used the OVID interface to electronically search in
October 2013 the following databases, starting with the
dates of their inception: MEDLINE, EMBASE, and
CINAHL. OVID is a platform that provides access to on-
line bibliographic databases, academic journals, and other
products, chiefly in the area of health sciences. We also
electronically searched in October 2013 the Cochrane
Central Register of Controlled Trials (CENTRAL). We did
not use any study design filter, as we wanted to capture
different types of study designs, particularly both random-
ized and non-randomized studies. We did not use lan-
guage or date restrictions. Additional file 1 lists the search
strategies used. We removed duplicates using the ‘find
duplicates’ function in the EndNote software. In addition
to the search of electronic databases, we reviewed the ref-
erences lists of relevant papers; contacted experts; and
searched personal files for both published and unpub-
lished studies.
Selection process
The reviewers were organized into two teams of two.
Prior to starting the selection process, we conducted
calibration exercises to clarify the eligibility criteria. We
reviewed 100 citations with every exercise. We achieved
agreement by the third exercise. At that point, the two
review teams started screening titles and abstracts of
identified citations in duplicate and independently. We
obtained the full texts for citations judged as potentially
eligible by at least one reviewer. Then, the two review
teams screened the full texts in duplicate and independ-
ently for eligibility. They used a standardized and pilot
tested full text screening form. The reviewers compared
results and resolved disagreements by discussion or with
the help of a third reviewer. We calculated agreement
between reviewers for full text screening using the kappa
statistic.
Data abstraction process
The two review teams abstracted data from eligible stud-
ies in duplicate and independently. They used a stan-
dardized and pilot tested data abstraction form with
detailed instructions. Then, the reviewers compared re-
sults and resolved disagreements by discussion or with
the help of a third reviewer. The data items abstracted
included:
 Description of the study device
 Study design
 Characteristics of participants and setting
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 Description of the intervention
 Description of the control
 Outcomes assessed and statistical results
 Funding and disclosed conflicts of interest
Risk of bias assessment
The two review teams assessed the risk of bias in each
study in duplicate and independently. They used a stan-
dardized and pilot tested data abstraction form with de-
tailed instructions. Then the reviewers compared results
and resolved disagreements by discussion or with the
help of a third reviewer. According to recommendations
outlined in the Cochrane Handbook, we used the follow-
ing criteria for assessing the risk of bias in randomized
studies:
 Inadequate sequence generation;
 Inadequate allocation concealment;
 Lack of blinding of participants, providers, data
collectors, outcome adjudicators, and data analysts
 Incompleteness of outcome data;
 Selective outcome reporting, and other bias.
We used the following criteria for assessing the risk of
bias in non-randomized studies:
 Failure to develop and apply appropriate eligibility
criteria
 Flawed measurement of exposure
 Flawed measurement of outcome
 Failure to adequately control confounding
 Incomplete follow-up
We judged each potential source of bias as high, low
or unclear risk of bias.
Data synthesis
For categorical data, we calculated the relative risk (RR)
for each outcome for each study. RR refers to the risk in
the intervention group or period (e.g., the introduction of
a safety device) relative to the risk in the control group or
period (e.g., using a device without a safety feature).
We assumed that variability in the population, inter-
ventions, control, and outcome measurements across
studies will introduce heterogeneity in findings across
those studies. To minimize this heterogeneity, we ana-
lyzed separately data for sharps injury prevention syrin-
ges and data for reuse prevention syringes. Also we
analyzed separately different measurement of the same
outcome, e.g., NSI per device and NSI per HCW. In
order to deal with residual heterogeneity, we then
pooled the results of studies using Mantel-Haenszel
method (with hybrid inverse variance weighting) to ac-
commodate random-effects. We did not choose the
fixed-effects model because it assumes a common effect
size, and it is inaccurate with a very small number of
studies [16, 17]. In a random-effects meta-analysis the
treatment effects for the individual studies are assumed
to vary around some overall average treatment effect.
We tested results for heterogeneity across studies
using the I statistic. We considered heterogeneity to be
substantial if I is greater than 50 %. We planned to cre-
ate inverted funnel plots of individual study results plot-
ted against sample size in order to check for possible
publication bias.
Sensitivity analysis
We identified two studies that assessed both devices for
intravenous injections or phlebotomy and devices for
intramuscular, subcutaneous or intradermal injections,
without providing data separately for the different types
of devices [18, 19]. In a post hoc decision, we included
these studies in the main analysis but excluded them in
a sensitivity analysis to test the impact of their data on
the final results. We used the freely available software
RevMan 5.1.0 for all analyses [20].
Subgroup analysis
We planned to explain heterogeneity, if present, by con-
ducting subgroup analyses based on the following fac-
tors: route of injection (intramuscular, intradermal,
subcutaneous), the type of device, level of expertise of
HCWs, and time of injury (before, during, or after the
injection). In order to assess the effects of reuse preven-
tion devices, and given we did not identify any study
assessing a device that is purely a reuse prevention de-
vice, we conducted a subgroup analyses of studies of de-
vices that qualified as both reuse prevention devices and
sharps injury prevention devices [15, 21, 22].
Quality of evidence assessment
We assessed the quality of evidence by outcome using
the GRADE methodology [23].
We produced a GRADE Evidence Profile to summarize
the statistical findings and quality of evidence by outcome.
Results
Study selection
Figure 1 shows the study flow. Out of a total of 6566
identified citations, we judged nine as eligible for this
systematic review [15, 18, 19, 21, 22, 24–27]. Agreement
between reviewers for full text screening was high
(kappa statistic = 1). Additional file 2 provides the list of
the 32 excluded studies with the following reasons for
exclusion: reporting on preferences, acceptability or
feasibility (n = 5); reporting economic analysis (n = 4);
evaluating glucometer lancets (n = 1); reporting data not
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in healthcare setting (n = 1); and evaluating intravenous in-
jection or phlebotomy safety devices (n = 22) [10, 28–57].
Study characteristics
Additional file 3 provides the list of the nine included
studies with detailed description of their characteristics.
Type of injection
Out of the nine included studies, five assessed devices
for intravenous injection or phlebotomy, in addition to
intramuscular, subcutaneous or intradermal injection
devices [15, 18, 19, 24, 27]. Of these five studies, three
provided data separately for the different types of devices
[15, 24, 27]. The remaining two studies reported data
combined for the different type of devices [18, 19].
Types of devices
Out of these nine studies, six assessed devices that qual-
ify as sharps injury prevention devices [18, 19, 24–27],
while three assessed devices that qualify as both sharps
injury prevention devices and reuse prevention devices
[15, 21, 22].
No studies included a comparison between active and
passive devices. Two studies reported SIDs with active
safety features [22, 26], two studies reported SIDs with
passive safety features [19, 21] and 5 studies had SIDs
with both active and passive or unspecified safety fea-
tures [15, 18, 24, 25, 58].
Device brand
Six specified the device brand and/or the manufacturer:
 Monoject™ Safety Syringe by Sherwood Medical [21]
 VanishPoint® by Retractable Technologies, Inc. [15, 22]
 SafetyGlide™ devices [19], Eclipse™ [25, 27] by
Becton Dickinson
 Surshield™ device by Terumo [27]
The remaining three studies specified neither the
brand nor the manufacturer [18, 24, 26].
Funding
Five studies reported their funding sources as follows:
Fig. 1 Study flow
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 Sherwood Medical; [21]
 Becton Dickinson; [19]
 National Institute of Allergy and Infectious Diseases;
the Centers for Disease Control and Prevention; and
the Prevention Epicenters; [24]
 Directorate General of Public Health of the
Autonomous Community of Valencia, Spain; [27]
 Dutch Ministry of Social Affairs and Employment
support; [25]
The remaining four studies did not report their fund-
ing sources [15, 18, 22, 26]. Two of these studies evaluated
VanishPoint® by Retractable Technologies, Inc. [15, 22]
while the other two specified neither the brand nor the
manufacturer of the device under evaluation [18, 26].
Conflicts of interest
Two studies reported that their authors had no conflicts
of interest [26, 27] The remaining studies did not pro-
vide conflicts of interest disclosures.
Study design
One study was a cluster prospective randomized con-
trolled trial [25]. The remaining eight studies were non-
randomized and used a before and after study design.
Out of these 8 studies, five collected data prospectively
[15, 19, 21, 24, 27] while three collected the data retro-
spectively [18, 22, 26].
Settings
Included studies were all conducted in the following
high income countries: Australia (n = 1); [15] Germany
(n = 1); [26] Netherlands (n = 1); [25] Spain (n = 1); [27]
United Kingdom (n = 1); [19] and United States (n = 4)
[18, 21, 22, 24].
Intervention
Interventions consisted of the introduction of the safety
devices detailed above under “Device brand”. For seven
studies, it was reported that healthcare workers received
some form of educational intervention with regards to
using the safety devices [19, 21, 22, 24–27].
Control
All included studies reported using “standard”, “conven-
tional” or “traditional” syringes in the ‘before’ phase.
Fig. 2 Risk of bias summary: review authors’ judgements about each
risk of bias item for the included randomized study
Fig. 3 Risk of bias summary: review authors’ judgements about each
risk of bias item for each included non-randomized study
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One study reported conducting a needle safety workshop
in the control group [25].
Outcomes
All studies assessed needle stick injuries among health-
care workers. None of the studies reported valuable
data on any of the other outcomes of interest. Whitby
et al. reported the following: “No significant increase in
bloodstream infections was detected during the study
period” [15].
Risk of bias within studies
Additional file 4 details and Fig. 2 summarizes the risk of
bias in the included randomized study. The trial was at high
risk of bias in relation to four out of 7 criteria assessed.
Additional file 5 details and Figs. 3 and 4 summarize
the risk of bias in the included non-randomized studies.
While the non-randomized studies were generally at low
risk for bias in relation to the appropriateness of eligibil-
ity criteria, measurement of the intervention, and meas-
urement of the outcome, they were all at unclear risk of
bias in relation to dealing with confounding and com-
pleteness of data.
Meta-analyses for sharps injury prevention syringes
Eligible studies reporting on the needlestick injuries
(NSI) used two main types of statistics: incidence of
NSI per device used (or purchased) [19, 21, 22, 27], and
incidence of NSI per healthcare worker [15, 18, 24–26].
We conducted separate meta-analyses for these differ-
ent statistics. One study reported incidence of NSI per
patient [27].




The meta-analysis of four studies resulted in a pooled
relative risk of 0.08 [95 % Confidence Interval (CI) 0.02,
0.27] (Fig. 5) [19, 21, 22, 27]. The I value was 51 %. The
inverted funnel plot, although based on only five studies,
did not suggest any publication bias (Fig. 6). The sensitiv-
ity analysis excluding the one study that did not report
separately data for devices for intramuscular, subcutane-
ous or intradermal injection devices, [19] resulted in a
pooled relative risk of 0.12 [95 % CI 0.02, 0.75] and I value
of 50 %.
NSI per healthcare worker
The meta-analysis of five studies resulted in a pooled
relative risk of 0.54 [0.41, 0.71] (Fig. 7) [15, 18, 24–26].
The I value was 43 %. The quality of evidence was rated
as moderate (Table 1). Of note, one of the included stud-
ies reported data based on a time-series analysis, but we
Fig. 4 Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included
non-randomized studies
Fig. 5 NSI per device for injury prevention devices
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opted to analyze it as a before and after study in order
to include it in the meta-analysis. The sensitivity analysis
excluding the one study that did not report separately
data for devices for intramuscular, subcutaneous or
intradermal injection devices [18], resulted in a pooled
relative risk of 0.53 [0.36, 0.79] and I value of 56 %.
Restricting the analysis to the only included randomized
trial resulted in a relative risk of 0.72 [0.30, 1.77].
Other outcomes
None of the included studies reported data for the
remaining outcomes of interest for sharps injury preven-
tion syringes. Whitby et al. made the following statement
without reporting any statistical data: “No significant in-
crease in bloodstream infections was detected during the
study period” [15].
Meta-analyses for reuse prevention syringes
As stated earlier, three studies reported on devices that
qualified as both reuse prevention devices and injury
protection devices [15, 21, 22]. Therefore, we conducted
subgroup analyses of those studies.
Needlestick injuries
NSI per device: The meta-analysis of two studies re-
sulted in a pooled relative risk of 0.07 [0.01, 0.43] (Fig. 8)
[21, 22]. The I value was 41 %.
NSI per healthcare worker: Data from one eligible
study indicate a RR of 0.40 [0.27, 0.59] (Fig. 9) [15]. The
quality of evidence was rated as moderate (Table 2).
Other outcomes
None of the included studies reported data for the
remaining outcomes of interest for reuse prevention sy-
ringes. As mentioned above, Whitby et al. made the fol-
lowing statement without reporting any statistical data:
“No significant increase in bloodstream infections was
detected during the study period” [15].
Additional analyses
Although we planned to conduct subgroup analyses to
explain heterogeneity, we did not have the opportunity
to conduct them mainly because of the relatively small
number of studies per analysis. Another reason is the
lack of reported data on some of the factors based on
which we planned to conduct the analyses: the type of
device, level of expertise of HCWs, and time of injury
(before, during, or after the injection).
Also, studies did not consistently report stratified out-
come data by route of injection (intramuscular, intrader-
mal, subcutaneous).
Discussion
In summary, we identified moderate quality evidence
that sharp injury prevention syringes reduce the inci-
dence of needlestick injuries per healthcare worker. We
identified no studies, meeting eligibility criteria for inclu-
sion and reporting data for: HIV, HBV, and HCV infec-
tions amongst healthcare workers; nor studies, meeting
eligibility criteria for inclsion and reporting on the effect
of reuse prevention syringes on the reuse of syringes;
nor HIV, HBV, and HCV infections amongst patients.
The main limitation in the literature is the lack of
evaluation of the effects of the safety devices on out-
comes other than needlestick injuries, whether benefits
or harms.
Particularly relevant outcomes include the reuse of sy-
ringes, or blood borne infections, particularly HIV, HBV,
and HCV amongst healthcare workers or patients.
Another limitation related to meta-analytical tech-
niques, is that heterogeneity may be underestimated
Fig. 6 Inverted funnel plot for the outcome: NSI by device for injury
prevention devices
Fig. 7 NSI per healthcare worker for injury prevention devices
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Table 1 Evidence profile for sharp injury prevention syringes versus single use disposable syringes when used by healthcare workers to deliver intramuscular, subcutaneous or
intradermal injections
Quality assessment № of patients Effect Quality Importance
№ of
studies
Study design Risk of
bias








Absolute (95 % CI)





Not serious Not serious Not serious Large effect
size




9 fewer per 1000 (from 6














especially when analyzing a small number of studies
[59]. That is why we opted to use the random effect
model irrespective of the value of I statistic. Also, given
the included studies are relatively old [60], it is likely
that publication bias exists and we were underpowered
to detect it. Finally, one has to consider that the ob-
served decrease in needle stick injuries shown by the
before-after studies, may reflect time trends related to
factors such as changes in the legislation, hospital pol-
icies, standards of reporting of needle stick injuries.
We have identified two other systematic reviews ad-
dressing questions that are similar but not the same as
our question [8, 61]. A Cochrane review addressed
different types of safety devices for preventing percutan-
eous exposure injuries caused by needles in healthcare
personnel [8]. They found “no clear evidence that the
introduction of safe injection devices changed the NSI
rate”. In fact, the Cochrane review included only four
studies potentially relevant to our review (i.e., injection
devices) [18, 25, 27, 62].
While we included three of these studies [18, 25, 27],
we excluded the fourth because it was conducted in an
educational setting, as opposed to a healthcare delivery
setting [62]. Moreover, they analysed two of those stud-
ies separately because they reported on multiple safety
devices [18, 27]. In our review, we abstracted from those
two studies data specific to injection devices and in-
cluded them in the meta-analysis.
In addition, we included six additional studies not
identified by the Cochrane review.
Indeed, the differences in rating the quality of evidence
between the Cochrane review and our review could be
explained by the differences in study inclusion and the
challenges with inter-rater reliability of assessing the
quality of evidence [63].
Another review published by the Health and Safety
Laboratory for the Health and Safety Executive 2012,
addressed different types of safety devices for preventing
percutaneous exposure injuries caused by needles in
healthcare personnel [61]. They found “there was suffi-
cient published evidence to consider the use of safer
sharps devices to reduce the incidence of sharps in-
juries amongst UK healthcare workers”. In fact, this
review included only seven studies potentially relevant
to our review (i.e., injection devices) [10, 18, 27, 29,
39, 44, 50]. While we included three of these studies
[10, 18, 27], we excluded the other four [29, 39, 44, 50]
because these were evaluating intravenous injection or
phlebotomy safety devices. Furthermore, they included
seventeen other studies that we judged as not eligible for
our review.
There is paucity of data about the cost or cost-
effectiveness of introducing those devices into healthcare
settings. Valls et al. reported that the introduction of
sheathed needles for subcutaneous and intramuscular
drug administration led to the following changes in
cost: −0.010 on hospital wards per patient-day and
0.021 in the emergency department per patient [58].
Whitby et al. reported $46,000 increase in the annual
budget of the hospital upon introduction of retractable
syringes [15].
Conclusions
The findings of this study have important implications
for HCWs practice. Indeed, the introduction of sharps
injury prevention devices into healthcare settings is
likely to reduce needlestick injuries. Healthcare man-
agers planning to introduce those devices need to
consider the cost related to their introduction. They
also should do that as part of a comprehensive injec-
tion safety program. Such program would include
education about the risks associated with accidental
injuries, training in using the safety devices, surveil-
lance and reporting of needle stick injuries among
Fig. 8 NSI per device for reuse prevention devices
Fig. 9 NSI per healthcare worker for reuse prevention devices
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Table 2 Evidence profile for sharp reuse prevention syringes versus single use disposable syringes when used by healthcare workers to deliver intramuscular, subcutaneous or
intradermal injections
Quality assessment № of patients Effect Quality Importance
№ of
studies
Study design Risk of
bias









Absolute (95 % CI)
HIV, HBV and HCV infections amongst patients: not reported
Critical











16 fewer per 1000 (from 11














HCWs, monitoring and evaluation of the program
implementation, immunization of healthcare workers
against HBV, and post exposure prophylaxis. In addition,
administrators should involve healthcare workers in select-
ing the devices. Given the paucity of data on the effective-
ness of reuse prevention syringes, healthcare managers
need to consider their use mainly in settings with high
rates of syringe reuse and high prevalence of blood
borne pathogens.
The findings of this study have also important research
implications. Future studies should assess the impact of
introducing safety devices on reuse rates, and on incidence
of blood borne infections amongst healthcare workers and
patients. In terms of methodology, randomized trials with
standardized methods for measuring incidence of sharps
injuries would provide better quality evidence relative to
currently available evidence. There is also a need to con-
duct cost-effectiveness studies for different settings, par-
ticularly low and middle income countries.
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